公开(公告)号：US20240167039A1

公开(公告)日：2024-05-23

申请号：US18057676

申请日：2022-11-21

申请人： NATIONAL YANG MING CHIAO TUNG UNIVERSITY

发明人： Wei-Ting LIN ,  Hao-Hsiang WU ,  Oscar Kuang-Sheng LEE ,  Jennifer Hui-Chun HO

IPC分类号： C12N15/113 ,  A61P11/00 ,  C12N5/0775

CPC分类号： C12N15/1135 ,  A61P11/00 ,  C12N5/0667 ,  C12N2310/141 ,  C12N2501/115 ,  C12N2501/148 ,  C12N2501/24

摘要： The present disclosure provides a method for treating and/or ameliorating a lung injury or inflammation in the lung, and/or promoting polarization of macrophages in a subject in need thereof, wherein the method comprises administering microRNA-7704 (miR-7704) or a composition comprising miR-7704 to the subject.

公开(公告)号：US09587223B2

公开(公告)日：2017-03-07

申请号：US14010578

申请日：2013-08-27

申请人： Asterias Biotherapeutics, Inc.

发明人： Ramkumar Mandalam ,  Saadia Faouzi ,  Isabelle Nadeau ,  Kristina Pfendler-Bonham ,  Namitha Rao ,  Melissa K. Carpenter ,  Lakshmi Rambhatla ,  Choy-Pik Chiu

IPC分类号： C12N5/071

CPC分类号： C12N5/067 ,  C12N2500/30 ,  C12N2500/36 ,  C12N2500/62 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/119 ,  C12N2501/12 ,  C12N2501/13 ,  C12N2501/148 ,  C12N2501/155 ,  C12N2501/23 ,  C12N2501/33 ,  C12N2501/335 ,  C12N2501/385 ,  C12N2501/39 ,  C12N2502/13 ,  C12N2503/02 ,  C12N2506/02 ,  C12N2533/90 ,  C12N2533/92

摘要： This disclosure provides a newly developed strategy and particular options for differentiating pluripotent stem cells into cells of the hepatocyte lineage. Many of the protocols are based on a strategy in which the cells are first differentiated into early germ layer cells, then into hepatocyte precursors, and then into mature cells. The cells obtained have morphological features and phenotypic markers characteristic of human adult hepatocytes. They also show evidence of cytochrome p450 enzyme activity, validating their utility for commercial applications such as drug screening, or use in the manufacture of medicaments and medical devices for clinical therapy.

摘要翻译： 本公开提供了一种新开发的策略和将多能干细胞分化成肝细胞谱系细胞的特定选择。 许多方案都是基于这样的策略，其中细胞首先分化成早期胚层细胞，然后分化成肝细胞前体，然后进入成熟细胞。 获得的细胞具有形态学特征和人成人肝细胞特征的表型标志物。 它们还显示细胞色素p450酶活性的证据，验证其在商业应用中的用途，例如药物筛选，或用于制备用于临床治疗的药物和医疗装置。

公开(公告)号：US20160348071A1

公开(公告)日：2016-12-01

申请号：US15234839

申请日：2016-08-11

申请人： Celavie Biosciences, LLC

发明人： Oleg V. Kopyov

IPC分类号： C12N5/0797 ,  A61K35/30

CPC分类号： C12N5/0623 ,  A01N1/0205 ,  A01N1/0221 ,  A61K35/12 ,  A61K35/30 ,  A61K35/545 ,  C12N5/0607 ,  C12N2500/14 ,  C12N2500/38 ,  C12N2500/46 ,  C12N2500/90 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/148 ,  C12N2501/235

摘要： Pluripotent cells that are immunopositive for both the neural progenitor marker nestin and a pluripotent cell marker are provided. The cells exhibit rapid doubling times and can be maintained in vitro for extended periods. Also provided are cell cultures containing the pluripotent cells, a method of transplanting human pluripotent cells to a host, and a method of reducing seizure activity in a subject. These pluripotent cells, when transplanted into the ventricle of a host animal, migrate to the site of damage and adopt a suitably corrective phenotype, resulting in both structural and functional restoration.

公开(公告)号：US20160256672A1

公开(公告)日：2016-09-08

申请号：US15019938

申请日：2016-02-09

申请人： CEDARS-SINAI MEDICAL CENTER

发明人： Vaithilingaraja Arumugaswami ,  Clive Svendsen

IPC分类号： A61M37/00 ,  A61M1/16 ,  C12N5/071

CPC分类号： C12N5/067 ,  A61M1/3489 ,  A61M2202/09 ,  C12N5/0075 ,  C12N2500/62 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/12 ,  C12N2501/148 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/165 ,  C12N2501/237 ,  C12N2501/39 ,  C12N2501/415 ,  C12N2506/45 ,  C12N2533/52

摘要： Human induced pluripotent stem cell (iPSC) technology combined with a hollow fiber based bioartificial liver (BAL) device can benefit patients with liver failure. Defined iPSC lines can provide unlimited supply of functional hepatocytes by developing iPSC derived hepatocytes (iHeps). Disclosed herein is a protocol for deriving metabolically active hepatocytes from iPSCs. In some embodiments, iHeps were cultured on microcarrier beads in spinner flasks. Subsequently, the iHep-microcarrier complexes were loaded into the extracapillary space of a hollow fiber bioreactor cartridge and cultured using closed circuit continuous flow system. The iHeps secreted human albumin, prothrombin and apolipoprotein B into the hollow fiber intracapillary space media which indicated the maintenance of plasma protein secretory function. In addition, the continuous flow system improved the maturation of iHeps. Thus, the iPSC hepatocytes in the bioartificial liver device maintained the secretory function and exhibited cell maturation.

摘要翻译： 人类诱导多能干细胞（iPSC）技术与基于中空纤维的生物人造肝（BAL）装置结合可以使肝衰竭患者受益。 定义的iPSC系可以通过开发iPSC来源的肝细胞（iHeps）来提供功能性肝细胞的无限供应。 本文公开了用于从iPSC衍生代谢活性肝细胞的方案。 在一些实施方案中，将iHeps在旋转瓶中的微载体珠上培养。 随后，将iHep-微载体复合物加载到中空纤维生物反应器柱的毛细血管腔内，并使用闭路连续流动系统进行培养。 iHeps将人白蛋白，凝血酶原和载脂蛋白B分泌到中空纤维内腔内空间介质中，表明维持血浆蛋白分泌功能。 此外，连续流动系统改善了iHeps的成熟。 因此，生物人工肝脏装置中的iPSC肝细胞维持分泌功能并显示细胞成熟。

公开(公告)号：US20130251686A1

公开(公告)日：2013-09-26

申请号：US13890787

申请日：2013-05-09

申请人： NEURALSTEM, INC. ,  REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Karl K. Johe ,  Thomas G. Hazel ,  Martin Marsala ,  Osamu Kakinohana

IPC分类号： A61K35/30

CPC分类号： A61K35/30 ,  A61K9/0085 ,  C12N5/0623 ,  C12N2501/11 ,  C12N2501/113 ,  C12N2501/115 ,  C12N2501/148

摘要： The invention relates generally to methods of treating spasticity, rigidity, or muscular hyperactivity conditions by introducing a portion of an expanded population of neural stem cells into an area of a recipient spinal cord.

摘要翻译： 本发明一般涉及通过将一部分扩大的神经干细胞群引入受体脊髓的区域来治疗痉挛，僵硬或肌肉过度活动的方法。

公开(公告)号：US20130115225A1

公开(公告)日：2013-05-09

申请号：US13627655

申请日：2012-09-26

申请人： Keio University

发明人： Chie Kudo ,  Yutaka Kawakami

IPC分类号： C07K16/28 ,  C07K16/18 ,  C12N15/113

CPC分类号： C07K16/2866 ,  A61K31/00 ,  A61K38/1709 ,  A61K38/1793 ,  A61K38/195 ,  A61K2039/505 ,  C07K14/4702 ,  C07K16/18 ,  C07K16/24 ,  C07K16/30 ,  C07K2317/73 ,  C12N5/0693 ,  C12N15/113 ,  C12N2310/14 ,  C12N2501/148 ,  C12N2502/1114 ,  C12N2502/1157 ,  C12N2502/30 ,  C12N2510/00

摘要： The invention features methods for inhibiting enhancement of expression of a FoxP3 gene in a cell, methods for inhibiting induction of differentiation of a cell into a regulatory T cell, methods for reducing immunosuppression, methods for stimulating tumor immunity, and methods for treating a patient with a tumor. The methods of the invention involve suppressing function of an FSTL1 protein in the cell. In the methods of the invention, function of an FSTL1 protein in the cell may be suppressed using an anti-FSTL1 antibody.

摘要翻译： 本发明的特征在于抑制细胞中FoxP3基因表达增强的方法，抑制诱导细胞分化成调节性T细胞的方法，减少免疫抑制的方法，刺激肿瘤免疫的方法以及用于治疗患者的方法 肿瘤 本发明的方法涉及抑制细胞中FSTL1蛋白的功能。 在本发明的方法中，可以使用抗FSTL1抗体抑制细胞中FSTL1蛋白的功能。

公开(公告)号：US08283168B2

公开(公告)日：2012-10-09

申请号：US11993432

申请日：2006-06-23

申请人： Gordon M. Keller ,  Paul Gadue

发明人： Gordon M. Keller ,  Paul Gadue

IPC分类号： C12N5/00 ,  C12N5/02

CPC分类号： C12N5/067 ,  C12N5/0603 ,  C12N5/0606 ,  C12N5/0607 ,  C12N2500/90 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/12 ,  C12N2501/148 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/385 ,  C12N2501/40 ,  C12N2501/415 ,  C12N2506/02 ,  C12N2506/03

摘要： The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy. The present invention further provides a method of generating hepatocytes, cell populations enriched for hepatocytes, and a method of hepatocyte replacement therapy.

摘要翻译： 本发明提供富集中内胚层和中胚层的细胞群以及富含内胚层的细胞群。 本发明的细胞群可用于产生用于细胞替代疗法的细胞。 本发明还提供了产生肝细胞的方法，富含肝细胞的细胞群，以及肝细胞替代疗法。

公开(公告)号：US20120070418A1

公开(公告)日：2012-03-22

申请号：US13304162

申请日：2011-11-23

申请人： Oleg V. Kopyov

发明人： Oleg V. Kopyov

IPC分类号： A61K35/30 ,  A61P19/04 ,  A61B19/02 ,  A61B8/00 ,  A61M5/178 ,  A61P19/00 ,  A61P19/02

CPC分类号： A01N1/021 ,  A61K35/545 ,  C12N5/0607 ,  C12N5/0623 ,  C12N2500/14 ,  C12N2500/38 ,  C12N2500/46 ,  C12N2500/90 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/148 ,  C12N2501/235

摘要： The stem cells that can be propagated and maintained for extended periods of time in culture in the absence of a feeder layer, and can be used to repair tissue damage. These cells are derived from fetal tissues and are able to repair different types of damage in musculoskeletal system, with significantly greater efficacy than stem cells derived from adult tissues. These cells are hypoimmunogenic and can be used for allogeneic transplantation to vertebrate hosts having disease and/or damage in musculoskeletal and other tissues. The cells can be administered by direct injection to the site in need of repair or by systemic (e.g., intravenous) administration. The stem cells of the invention are capable of migrating to the sites in need of repair, and of adopting a phenotype most appropriate to the nature of the damage, injury or disease.

摘要翻译： 干细胞可以在不存在饲养层的情况下在培养物中传播和维持较长时间，并可用于修复组织损伤。 这些细胞衍生自胎儿组织，能够在肌肉骨骼系统中修复不同类型的损伤，与成体组织的干细胞相比，功效显着更大。 这些细胞是低免疫原性的，并且可以用于在肌肉骨骼和其他组织中具有疾病和/或损伤的脊椎动物的同种异体移植。 可以通过直接注射到需要修复的部位或通过全身（例如静脉内）给药来施用细胞。 本发明的干细胞能够迁移到需要修复的部位，并且采用最适合损伤，损伤或疾病性质的表型。

公开(公告)号：US20110293667A1

公开(公告)日：2011-12-01

申请号：US13007250

申请日：2011-01-14

申请人： Dolores Baksh ,  Xianyan Wang ,  Matthew Q. Wong ,  Lan Cao ,  Parid Sava ,  Thomas Bollenbach ,  Esin Yesilalan

发明人： Dolores Baksh ,  Xianyan Wang ,  Matthew Q. Wong ,  Lan Cao ,  Parid Sava ,  Thomas Bollenbach ,  Esin Yesilalan

IPC分类号： A61K35/12 ,  A61K35/44 ,  A61K35/50 ,  A61K35/34 ,  C12P21/00 ,  A61K9/00 ,  A61P19/04 ,  A61P19/08 ,  A61P21/00 ,  A61K35/28 ,  A61K35/32

CPC分类号： C12N5/0663 ,  A61K2035/124 ,  A61L27/3633 ,  A61L27/3804 ,  A61L27/3834 ,  A61L27/3886 ,  A61L27/3891 ,  C12N5/0667 ,  C12N5/0668 ,  C12N2500/25 ,  C12N2500/38 ,  C12N2500/90 ,  C12N2501/02 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/148 ,  C12N2501/39 ,  C12N2533/90

摘要： Bioengineered constructs are formed from cultured cells induced to synthesize and secrete endogenously produced extracellular matrix components without the requirement of exogenous matrix components or network support or scaffold members. The bioengineered constructs of the invention can be produced with multiple cell types that can all contribute to producing the extracellular matrix. Additionally or alternatively, one of the multiple cell types can be delivered to a site in the body via the endogenously produced extracellular matrix components to achieve various therapeutic benefits.

摘要翻译： 生物工程化构建体由诱导合成和分泌内源性产生的细胞外基质组分的培养细胞形成，而不需要外源基质组分或网络支持物或支架构件。 本发明的生物工程化构建体可以用多种可以有助于产生细胞外基质的细胞类型产生。 另外或替代地，多种细胞类型中的一种可以通过内源产生的细胞外基质组分递送到体内的位点，以实现各种治疗益处。

公开(公告)号：US20110293666A1

公开(公告)日：2011-12-01

申请号：US13007201

申请日：2011-01-14

申请人： Xianyan Wang ,  Katherine C. Faria

发明人： Xianyan Wang ,  Katherine C. Faria

IPC分类号： A61K9/00 ,  A61K35/12 ,  A61K35/36 ,  A61K35/44 ,  A61K35/42 ,  A61K35/22 ,  A61K35/38 ,  C12N5/071 ,  A61K35/32

CPC分类号： A61L27/3633 ,  A61L27/3683 ,  A61L27/3804 ,  C12N5/0068 ,  C12N5/0698 ,  C12N2500/25 ,  C12N2500/36 ,  C12N2500/38 ,  C12N2500/40 ,  C12N2500/50 ,  C12N2500/90 ,  C12N2501/11 ,  C12N2501/148 ,  C12N2501/395 ,  C12N2502/094 ,  C12N2502/1323 ,  C12N2533/50 ,  C12N2533/92

摘要： Bioengineered constructs are formed from cultured cells induced to synthesize and secrete endogenously produced extracellular matrix components, e.g., without the requirement of exogenous matrix components or network support or scaffold members. The bioengineered constructs of the invention can be treated in various ways such that the cells of the bioengineered constructs can be devitalized and/or removed without compromising the structural integrity of the constructs. Moreover, the bioengineered constructs of the invention can be used in conjunction with biocompatible/bioremodelable solutions that allow for various geometric configurations of the constructs.

摘要翻译： 生物工程化构建体由诱导合成和分泌内源产生的细胞外基质组分的培养细胞形成，例如不需要外源基质组分或网络支持物或支架构件。 可以以各种方式处理本发明的生物工程化构建体，使得生物工程化构建体的细胞可以在不影响构建体的结构完整性的情况下失活和/或去除。 此外，本发明的生物工程化构建体可以与允许构建体的各种几何构型的生物相容/生物可重构溶液结合使用。